High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Author:
Affiliation:
1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
2. Department of Medicine, University of British Columbia, Vancouver, BC, Canada; and
3. Department of Medicine, University of Washington, Seattle, WA
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/134/7/636/1554299/bloodbld2019000905.pdf
Reference25 articles.
1. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017
2. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019
3. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study [published correction appears in J Clin Oncol. 2016;34(12):1430];Casulo;J Clin Oncol,2015
4. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era;Rivas-Delgado;Br J Haematol,2019
5. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS);Wagner-Johnston;Blood,2015
Cited by 128 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recent progresses of exosome–liposome fusions in drug delivery;Chinese Chemical Letters;2024-02
2. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies;Life Sciences;2024-02
3. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma;Blood Advances;2024-01-23
4. Treatment of relapsed follicular lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024
5. Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3